Faithful maintenance and propagation of eukaryotic genomes is ensured by three-step DNA ligation reactions used by ATP-dependent DNA ligases 1,2 . Paradoxically, when DNA ligases encounter nicked DNA structures with abnormal DNA termini, DNA ligase catalytic activity can generate and/or exacerbate DNA damage through abortive ligation that produces chemically adducted, toxic 59-adenylated (59-AMP) DNA lesions 3-6 . Aprataxin (APTX) reverses DNA adenylation but the context for deadenylation repair is unclear. Here we examine the importance of APTX to RNase-H2-dependent excision repair (RER) of a lesion that is very frequently introduced into DNA, a ribonucleotide. We show that ligases generate adenylated 59 ends containing a ribose characteristic of RNase H2 incision. APTX efficiently repairs adenylated RNA-DNA, and acting in an RNA-DNA damage response (RDDR), promotes cellular survival and prevents S-phase checkpoint activation in budding yeast undergoing RER. Structure-function studies of human APTX-RNA-DNA-AMP-Zn complexes define a mechanism for detecting and reversing adenylation at RNA-DNA junctions. This involves A-form RNA binding, proper protein folding and conformational changes, all of which are affected by heritable APTX mutations in ataxia with oculomotor apraxia 1. Together, these results indicate that accumulation of adenylated RNA-DNA may contribute to neurological disease.
Faithful maintenance and propagation of eukaryotic genomes is ensured by three-step DNA ligation reactions used by ATP-dependent DNA ligases 1, 2 . Paradoxically, when DNA ligases encounter nicked DNA structures with abnormal DNA termini, DNA ligase catalytic activity can generate and/or exacerbate DNA damage through abortive ligation that produces chemically adducted, toxic 59-adenylated (59-AMP) DNA lesions [3] [4] [5] [6] . Aprataxin (APTX) reverses DNA adenylation but the context for deadenylation repair is unclear. Here we examine the importance of APTX to RNase-H2-dependent excision repair (RER) of a lesion that is very frequently introduced into DNA, a ribonucleotide. We show that ligases generate adenylated 59 ends containing a ribose characteristic of RNase H2 incision. APTX efficiently repairs adenylated RNA-DNA, and acting in an RNA-DNA damage response (RDDR), promotes cellular survival and prevents S-phase checkpoint activation in budding yeast undergoing RER. Structure-function studies of human APTX-RNA-DNA-AMP-Zn complexes define a mechanism for detecting and reversing adenylation at RNA-DNA junctions. This involves A-form RNA binding, proper protein folding and conformational changes, all of which are affected by heritable APTX mutations in ataxia with oculomotor apraxia 1. Together, these results indicate that accumulation of adenylated RNA-DNA may contribute to neurological disease.
Previous studies indicate that abortive ligation ( Fig. 1a ) may occur during attempts to repair DNA lesions generated by oxidation [4] [5] [6] [7] or alkylation 7, 8 . We explored a much more abundant opportunity for abortive ligation, that is, during ribonucleotide excision repair (RER) [9] [10] [11] . RER is initiated when RNase H2 cleaves on the 59 side of a ribonucleotide found in a 59-RNA-DNA-39 junction (Fig. 1b , referred to hereafter as RNA-DNA junction). This event is estimated to generate more than 1,000,000 nicked RNA-DNA junctions per cell cycle in mice 10 and more than 10,000 nicked RNA-DNA junctions per cell cycle in budding yeast [11] [12] [13] . Our study was prompted by the fact that ribonucleotides are introduced into the nuclear genome at levels that are much greater than all known types of DNA damage combined, and evidence that DNA ligation in vitro is impaired at incised RNA-DNA junctions 1, 14 . We compared the ability of human DNA ligase I to seal a nick containing canonical 39-OH and 59-P termini to a nick containing a 39-OH and a 59-P attached to a rG that mimics a nick generated when RNase H2 initiates RER (Fig. 1b ). Greater than 95% of the nicked DNA substrate containing the 39-OH and 59-P termini was ligated within 10 min. In contrast, the presence of a single ribonucleotide (rG) on the 59 side of the nick (59 RNA substrate, Fig. 1b ) significantly impaired generation of the 39-nucleotide ligation product (,1% ligation at 10 min, Extended Data Fig. 1a ). Ligase I processing of the 59 RNA substrate also produced an additional species migrating at a size of ,20 nucleotides, that corresponds to a bona fide 59-adenylated product (59-AMP RNA-DNA ) ( Fig. 1b and Extended Data Fig. 1b ). The adenylated product comprises greater than 50% of all DNA ligase I catalytic events on the 59 RNA substrate at all time points measured ( Fig. 1c and Extended Data Fig. 1a ). Also, human DNA ligase III and bacteriophage T4 DNA ligase, but not Escherichia coli NADdependent LigA, generated similar amounts of ribonucleotide-triggered abortive ligation products (Fig. 1c ). Thus, incised RNA-DNA junctions *These authors contributed equally to this work. 1 are poor substrates for eukaryotic DNA ligase nick-sealing reactions, and also trigger abortive ligation at high frequency in vitro. Aprataxin deadenylase (APTX in mammals and Schizosaccharomyces pombe, and Hnt3 in Saccharomyces cerevisiae) reverses DNA adenylation [3] [4] [5] . Inactivation of APTX in ataxia oculomotor apraxia 1 (AOA1) [15] [16] [17] suggests that persistent adenylated DNA strand breaks drive cerebellar degeneration in neurological disease 4 . However, the molecular context for APTX deadenylation remains uncertain. To examine a potential role for APTX during RER, we compared steady-state kinetic parameters for deadenylation by human APTX on gel-purified abortive ligation substrates arising from metabolism of RNA-DNA junctions (59-AMP RNA-DNA ) to those representative of abortive ligation on DNA single-strand breaks created by reactive oxygen species 4 (59-AMP SSB ) ( Fig. 1d and Extended Data Fig. 1c ). Both substrates were efficiently processed with comparable rates (k cat 5 0.31 versus 0.37 s 21 ) with catalytic efficiencies that are ,30,000-fold higher than those reported on nucleotide substrates 18 . A ,6-fold higher k cat /K m for 59-AMP RNA-DNA versus 59-AMP SSB indicates that human APTX displays an in vitro preference for the RNA-DNA-derived substrates.
Both S. pombe Aptx and S. cerevisiae Hnt3 Aptx also harbour 59-AMP RNA-DNA deadenylase activity (Extended Data Fig. 1d , e). To determine whether Aptx deadenylates abortive ligation products generated at RNA-DNA junctions in vivo, we examined whether the phenotypes of budding yeast strains with varying capacity to incorporate and repair ribonucleotides were altered by Hnt3 Aptx deficiency ( Fig. 2) . A M644G variant of the leading strand replicase, DNA polymerase e (Pol e, encoded by the POL2 gene, see Extended Data Table 1 ), has increased capacity to incorporate ribonucleotides into DNA in vitro and in vivo 13, 19 . We generated heterozygous diploids in which one copy of HNT3 was replaced with the NatMX4 marker. Tetrad analysis showed that although HNT3 is dispensable for growth in a wild-type Pol e (POL2) strain, growth of pol2-M644G hnt3D haploids is severely impaired ( Fig. 2a ), with macroscopic colonies only observed after extended incubation (Extended Data Fig. 2a ).
We reasoned that the growth defect of the pol2-M644G hnt3D strain is linked to accumulation of persistent adenylated DNA strand breaks generated by DNA ligase processing of RNase H2 incised RNA-DNA junctions (that is, 59-AMP RNA-DNA ). To test whether RNase H2 activity contributes to the impaired growth of the pol2-M644G hnt3 mutant, we sporulated and dissected a diploid strain homozygous for deletion of the gene encoding the catalytic subunit of RNase H2 (RNH201).
Notably, deleting RNH201 (rnh201D) largely mitigated the growth defect of the pol2-M644G hnt3D mutant ( Fig. 2b, c ). This observation indicates that incision of ribonucleotides in DNA by RNase H2 generates an RER intermediate leading to production of 59-AMP RNA-DNA that requires deadenylation by Hnt3 Aptx (see model, Fig. 2e ).
Increased Rnr3 protein level is a sensitive indicator of S-phase checkpoint activation 12, 20 . An increased level of the Rnr3 subunit of ribonucleotide reductase was detected in pol2-M644G hnt3D cells (Fig. 2d , lane 6), but was reduced in the triple mutant pol2-M644G hnt3D rnh201D strain (lane 8) to a level equivalent to that of a pol2-M644G rnh201D mutant (lane 7). This suggests that failure of Hnt3 Aptx to deadenylate 59-AMP RNA-DNA lesions activates the S-phase checkpoint. We also tested hnt3D mutant strains for sensitivity to genotoxic stress caused by hydroxyurea (HU). HU treatment increases rNMP incorporation 10 and induces replication fork stalling. Growth of the pol2-M644G hnt3D mutant on rich medium was slowed, and survival in the presence of HU was reduced (Extended Data Fig. 2b, c) . Notably, deleting RNH201 reduced HU sensitivity to a level comparable to pol2-M644G rnh201D cells (Extended Data Fig. 2c ).
Next we examined the consequences of loss of Hnt3 function in yeast strains containing a Pol e variant with reduced capacity to incorporate ribonucleotides, pol2-M644L (ref. 13) . With fewer ribonucleotides in the genome, the pol2-M644L hnt3D mutant displayed normal growth ( Fig. 2c ) and was unaffected by deleting RNH201. The stark contrast between the consequences of loss of Hnt3 function in the pol2-M644G variant (high genomic ribonucleotides) versus the pol2-M644L mutant (reduced genomic ribonucleotides) is consistent with the model wherein Hnt3 Aptx deadenylates genotoxic abortive ligation intermediates arising during RER of ribonucleotides incorporated by Pol e during DNA replication ( Fig. 2e ). A genetic interaction between HNT3 and RNH201 is not apparent in a POL2 strain, possibly because adenylated RNA-DNA junctions may be removed by alternative nucleolytic processing, for example, mediated by Rad27 Fen1 and Mre11/Rad50/ Xrs2 Nbs1 nucleases 8 .
Having implicated aprataxins in processing 59-AMP RNA-DNA in vitro and in vivo, we aimed to define the molecular basis for 59-AMP RNA-DNA processing by human APTX. Structural analysis of the S. pombe APTX DNA complex revealed the architecture of the yeast Aptx HIT-Znf domain, and a basis for engagement of DNA ends 3 . However, the molecular basis for the APTX RNA-DNA interactions, and the mechanism of the APTX DNA damage direct reversal catalytic reaction, remain Leading strand synthesis (Pol ε)
Figure 2 | Yeast Hnt3 Aptx is critical for resolving abortive ligation
intermediates that arise after incision at genomic ribonucleotides by RNase H2. a, Tetrad analysis of HNT3/hnt3::natMX diploids. 1-8 are tetrad dissections and A-D are haploid spore colonies. Right: day 3 microscopic spore colonies in the pol2-M644G hnt3D strains. b, Tetrad analysis of HNT3/ hnt3::natMX diploids in the pol2-M644G rnh201D background. Plates imaged at 3 days. c, Deletion of HNT3 in the pol2-M644G mutator confers a slow growth phenotype that is eliminated by deleting RNH201. Doubling times (D t ) were calculated from cultures in the logarithmic phase of growth in rich medium at 30 uC. Average doubling time 6 s.d. are calculated from four biological replicates (eight for the pol2-M644G hnt3D genotype, *P , 0.0007; **P , 0.0011 (two-tailed t-test)). d, Immunoblotting of whole-cell extracts was performed using an antibody to Rnr3. e, RNase H2 cleavage at ribonucleotides incorporated during Pol e leading-strand DNA synthesis leads to abortive ligation intermediates requiring APTX processing. Deletion of HNT3 (hnt3D) or APTX deficiency in ataxia oculomotor apraxia 1 (AOA1) creates persistent adenylated strand breaks.
unclear (see Supplementary Discussion). The minimal catalytic domain of human APTX was mapped to residues 165-342 using deletion mutagenesis, limited proteolysis and deadenylation assays (Extended Data Fig. 3a -c). We then determined four X-ray crystal structures of: (1) an RNA-DNA-bound human APTX-59-AMP-RNA-DNA-Zn quaternary product complex; (2) a mimic of an adenylated RNA-DNA processing enzymatic transition state; (3) a DNA-only bound human APTX-59-AMP-DNA-Zn quaternary complex structure; and (4) an AOA1 mutant human APTX(K197Q) RNA-DNA bound quaternary product complex (see Supplementary Discussion, Extended Data Table 2 and Extended Data Fig. 3 ).
The APTX a-b histidine triad (HIT) fold domain 21 assembles with a DNA-binding Znf domain in human APTX RNA-DNA deadenylase ( Fig. 3b and Extended Data Figs 4 and 5). Close interactions between the HIT and Znf subdomains mould both the active site and the extended RNA-DNA damage-binding surface ( Fig. 3b and Extended Data Fig. 5 ). The 59-adenylate binding pocket and 59-ribonucleotide interaction surfaces localize to the intersection of the HIT and Znf domains (Fig. 3b, c) . The APTX-bound RNA-DNA junction is significantly distorted from B-form DNA (Extended Data Fig. 5a ). A two-point nucleic acid-protein interaction induces a ,15u bend in the RNA-DNA by anchoring the exposed 59-terminal RNA base stack and the 59-AMP lesion on one side, while engaging the opposite undamaged strand with an array of contacts from the Znf domain (Extended Data Fig. 5d-g) . Biochemical studies revealed that APTX disrupts Watson-Crick base pairing of the adenylated base pair 22 . In our structures, DNA distortions and capping of the RNA-DNA base-stack by the HIT domain amino-terminal helix (a1) provide a possible mechanism for un-pairing of the terminal rGNC base pair to gain access to the lesion (Extended Data Fig. 5b-g ). In the DNA-only bound human APTX structure, similar DNA distortions are observed, revealing that APTX processes adenylated RNA-DNA and DNA with an analogous mode of substrate engagement (Extended Data Fig. 6 and Supplementary Discussion). APTX sequesters the 59-AMP lesion into a hydrophobic active site recess in an extra-helical conformation that is rotated ,180u relative to the RNA-DNA helical axis ( Fig. 3c and Extended Data Fig. 5c ).
RNA-DNA damage detection and reaction chemistry are mediated by four stringently conserved APTX elements that converge on the 59ribonucleotide and 59-AMP lesion: HIT helix a1, the 'histidine triad' HWHWH loop (where H is histidine and W denotes a hydrophobic amino acid), the 'b2-b3' loop, and Znf helix a3 ( Fig. 3c and Extended Data The first step of the APTX reaction is proposed to generate a covalent enzyme-AMP intermediate 3, 22 , via an enzyme-nucleic acid transition state that poses a significant challenge to protein structural interrogation. To trap this transition state, we developed reaction conditions under which APTX activity is inhibited when co-incubated with adenosine, orthovanadate and a 59-phosphorylated RNA-DNA junction duplex (Extended Data Fig. 3g , h). Reaction of human APTX with these reagents in crystallo produced a mimic of the enzyme-RNA-DNA-AMP transition state intermediate for step 1 of a two-step deadenylation reaction ( Fig. 4a and Extended Data Fig. 3i, j) .
The HWHWH loop completely encircles the adenylated 59-ribonucleotide lesion ( Fig. 4) , with His 260 covalently bonded to a pentavalent coordinate vanadium atom in the transition state mimic complex (Fig. 4a, d and Extended Data Fig. 3i ). The transition state and product-bound structures support a two-step deadenylation reaction initiated by nucleophilic attack of the scissile pyrophosphate by His 260 (Fig. 4d ). Protein main-chain amides of Ser 255-Met 256 and salt bridging from His 201-His 262 stabilize this transition state (Fig. 4a ). His 251 is ideally positioned to protonate a 59-P leaving group, and binds 59-P together with Ser 255 and Lys 277. In the proposed reaction scheme (Fig. 4d) , step 1 generates an enzyme-AMP intermediate, which is then resolved via hydrolysis in step 2. Notably, in the product complex, a Na 1 ion (assigned by oxygen-ion bond lengths) with octahedral coordination binds between Ser 255 and 59-P (Fig. 4b) , indicating that although APTX activity is metal-independent, transient solvent cation binding stabilizes the product state, similar to third metal binding in DNA polymerase g 23 . 
LETTER RESEARCH
Human APTX is found in two markedly different conformations in the product-bound structure. The first conformation (the 'assembled active site' Fig. 4b and Extended Data Fig. 7a, b) has an intact active site characterized by close interactions between HIT a1 (Leu 171 and Trp 167) and the HWHWH loop, and correct positioning of His 260 for catalysis. This state has the His 260 imidazole ring hydrogen bonded to the His 268 main-chain carbonyl oxygen. In the second state (the 'disassembled active site'), a1 is displaced by ,4 Å relative to a rearranged HWHWH loop, and His 260 is flipped out of alignment for nucleophilic attack (compare Fig. 4b and c ). Structural overlays (Fig. 4e ) and interpolations between these two states ( Supplementary Videos 1 and 2) indicate that concerted conformational rearrangements sculpt the HWHWH loop, and may be linked to RNA-DNA substrate binding by a1 and HWHWH (Extended data Fig. 7b-e ). We propose that interactions between RNA-DNA and protein proximal to the active site regulate active-site conformations involving HIT a1. RNA/DNA-regulated assembly of the APTX active site may 'license' catalytic activity and also prevent inappropriate, nonspecific hydrolysis of nucleotides (for example, ATP or ADP hydrolysis). Discrimination against ATP cleavage may be critical for mitochondrial APTX isoforms that have previously been implicated in DNA damage repair in mitochondria 24 , because off-target catalysis could imbalance nucleotide pool levels.
Both missense and truncating APTX substitutions are linked to neurodegenerative disease [15] [16] [17] . On the basis of the human APTX structures determined here, we predict that most AOA1 mutations (D185E, A198V, P206L, G231E, R247X, V263G, D267G, W279X, W279R and R306X) will decrease protein stability by truncating the polypeptide or by altering the protein-folding core (Extended Data Fig. 8a ). Conformational differences between our RNA-DNA bound structures extend into the protein core (Extended Data Fig. 7a ). APTX conformational changes may thus be subject to mutagenic modulation in disease. We posit that differential impacts on protein folding, active-site chemistry and substrate induced-fit active site assembly may all contribute to the variable clinical outcomes observed in patients with APTX defects 17 .
One AOA1 mutation is found in the RNA-DNA substrate interaction cleft (K197Q) and two participate directly in active-site chemistry (H201R and H201Q) (Fig. 4a-c and Extended Data Fig. 8a) . The late-onset AOA1 variant APTX(K197Q) 17 displays significantly impaired deadenylation activity on both the 59-AMP SSB and 59-AMP RNA-DNA substrates (Extended Data Fig. 6b ). To understand the molecular basis for the K197Q defect, we determined a 1.90 Å X-ray structure of APTX(K197Q) bound to RNA-DNA and AMP that reveals the mutant protein harbours a distorted active-site pocket ( Fig. 4f and Extended Data Fig. 8b, c) . In the wild-type protein, Lys 197 participates in salt-bridging interactions with the 59-terminal sugar-phosphate backbone and the AMP lesion 29-hydroxyl. In the mutant, Gln 197 is rotated away from the substrate-binding pocket and substitutes direct protein-substrate interaction with a protein-water-substrate nucleic acid binding interaction, thus revealing that distortions in the APTX( K197Q) substrate-binding pocket underlie AOA1.
Our data indicate that during repair of non-canonical ribonucleotides introduced into DNA during replication of the nuclear genome, DNA ligases generate 59-adenylated RNA-DNA junctions that can elicit a DNA damage checkpoint response unless this is prevented by APTX deadenylase. In addition to frequent ribonucleotide incorporation by DNA replicases, rNTPs are used by RNA primase to initially His258 His258
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synthesize ,5% of the nascent lagging strand, and rNTPs are also incorporated during mitochondrial DNA replication 25, 26 , during translesion synthesis 27 , and during DNA repair 28 . Ribonucleotide incorporation during DNA repair may be more prevalent in non-proliferating cells because dNTP concentrations are lower 29, 30 , thereby increasing rNTP:dNTP ratios 30 . Thus, the late onset of AOA1 might partly reflect failure to deadenylate RNA-DNA junctions resulting from ribonucleotides incorporated in DNA transactions occurring over many years in quiescent neurons. It will be important in future work to establish quantitative measures of RNA-DNA adenylation to explore this hypothesis.
In this context, APTX acts in a nucleic acid transaction that is not exclusively DNA or RNA. Instead, using a reaction mechanism that is finely tuned to operate on RNA-DNA junctions, APTX acts in an RNA-DNA damage response (RDDR) to protect the genome from a compound insult, a ribosylated, adenylated 59 terminus. In a broader sense, it seems probable that other enzymes may also modulate the RDDR via the detection, processing and signalling of RNA-DNAderived structures posing threats to genomic integrity.
METHODS SUMMARY
Proteins were expressed in Escherichia coli and purified with standard procedures. All crystals were grown using sitting-drop vapour diffusion. X-ray diffraction data were all collected at 100 K at the Advanced Photon Source, beamlines 22-ID and 22-BM. Initial DNA-bound human APTX structures were solved by molecular replacement with the S. pombe Aptx-DNA complex (RCSB code 3SZQ). RNA-DNA-bound wild-type and mutant human APTX structures were solved by molecular replacement using the refined human APTX-DNA-bound model. S. cerevisiae strain construction and growth assays were performed as described 12 .
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
APTX protein expression and purification. An Escherichia coli codon-optimized coding sequence (GenScript) facilitated robust recombinant overexpression of human APTX. Human APTX full-length protein and truncated variants were expressed from pET15b as N-terminal 63His-tagged proteins in E. coli BL21(DE3) codon-plus cells (Novagen). APTX mutations were introduced using the Quickchange system (Stratagene). Cell cultures were grown at 37 uC in LB medium containing ampicillin (100 mg ml 21 ) and chloramphenicol (34 mg ml 21 ) until A 600 reached 0.8 to 1, at which time cells were cooled to 16 uC and grown for an additional 8-12 h, without IPTG induction. Cells were lysed by sonication in lysis buffer (50 mM Tris, pH 8.5, 500 mM NaCl, 10 mM imidazole, 0.01 g l 21 lysozyme, with Roche mini EDTA-free protease inhibitor). The soluble lysate was applied to Ni-NTA column (5 ml, Qiagen) and 63 His-tagged human APTX proteins were eluted in lysis buffer with 300 mM imidazole. The 63His tag was removed with overnight thrombin digestion (50 U) (Sigma) at 4 uC. Subsequent purification was achieved by size-exclusion chromatography (Superdex 75, GE healthcare in 50 mM Tris, pH 7.5, 500 mM NaCl, 5% glycerol, 0.1% b-mercaptoethanol) and cation exchange chromatography on a 5-ml Hi-Trap SP HP (GE Healthcare). S. pombe Aptx was expressed and purified as previously described 3 . DNA ligation reactions. For DNA ligation experiments, human DNA ligase I (residues 232-919) and DNA ligase III b (residues 1702862) catalytic domains were expressed and purified as described previously 1, 31 . Recombinant T4 DNA ligase and E. coli LigA were obtained from New England Biolabs. Ligation reactions (35 ml) contained DNA ligases (1 mM), 59-DNA substrate (50 nM, oligonucleotides 1, 2 and 4, Extended Data Fig. 3d ) or 59-RNA (50 nM, oligonucleotides 1, 2 and 5, Extended Data Fig. 3d ) in 10 mM Tris, pH 7.5, 2 mM MgCl 2 , 1 mM DTT, 1 mM ATP and 350 ng BSA. 5 ml aliquots of the reaction mixture were taken at 0, 10, 30, 60, 120 and 240 min and immediately heat inactivated in 8 M urea and 5% glycerol (5 ml) for 10 min. Ligation reaction products were analysed on 15% TBE-Urea gels (Invitrogen). Reaction products were analysed on 15% TBE-Urea gel (Invitrogen). Carboxytetramethylrhodamine (Tamra)-labelled reaction products were quantified on a Typhoon scanner (GE Healthcare). Limited proteolysis. Proteolysis reaction mixtures (60 ml) contained human APTX (22 mM) and protease (0.01 mg ml 21 chymotrypsin or 0.1 mg ml 21 trypsin) in protease reaction buffer (20 mM Tris, pH 7.5, 450 mM NaCl, 0.1% b-mercaptoethanol). A 10 ml aliquot of the reaction mixture was taken at 0, 5, 15, 30 and 60 min and immediately mixed with 1 mg ml 21 PMSF (1 ml), and heated in Novex SDS sample buffer (Invitrogen) at 95 uC for 10 min. Protease digestion reaction products were analysed by SDS-PAGE. Preparation of adenylated DNA substrates. The adenylated 59-AMP RNA-DNA substrate was generated by abortive ligation of human DNA ligase I on the 59-RNA duplex (oligonucleotides 1, 2 and 5, Extended Data Fig. 3d ). The 59-AMP SSB adenylated strand was generated in abortive ligation reactions (50 ml) with T4 DNA ligase (2400 U) (NEB) on a 59-SSB duplex (oligonucleotides 1, 3 and 4, Extended Data Fig. 3d ). Abortive ligation reactions were heat inactivated in 8 M urea at 95 uC for 10 min, and reaction products were fractionated in 20% TBE-urea gels for purification. The adenylated products were excised from the gel and extracted in 0.3 M sodium acetate pH 5.2 at 37 uC overnight, followed by desalting on Sep-Pak C18 cartridges (Waters). For APTX deadenylation analysis, the purified adenylated strands were then re-annealed with the appropriate complementary oligonucleotides (oligonucleotides 1 and 2 to form 59-AMP RNA-DNA , or oligonucleotides 1 and 3 to form 59-AMP SSB ). APTX deadenylation reactions. Deadenylation reactions for APTX proteintruncation mapping experiments (10 ml) contained 59-adenylated duplex 59-AMP SSB (30 nM) and human APTX (0.1 nM to 1 mM) in deadenylation reaction buffer (50 mM Tris, pH 8.0, 40 mM NaCl, 5 mM EDTA, 1 mM DTT and 5% glycerol). Reactions were incubated at 20 uC for 10 min, and inactivated by heating for 10 min at 100 uC following addition of 10 ml gel loading buffer (8 M urea, 50 mM Tris, pH 7.5, 25 mM EDTA, and 5% glycerol). For time course experiments, deadenylation reactions (40 ml) contained human APTX (2 nM), 59-adenylated duplex 59-AMP RNA-DNA (10 nM) or 59-AMP SSB (10 nM) in deadenylation reaction buffer. 5 ml aliquots of the reaction mixtures were taken at 0, 0.5, 1, 2, 5, 10 and 30 min and immediately heat inactivated in 8 M urea and 5% glycerol (5 ml). Reaction products were analysed on 15% TBE-urea gel (Invitrogen). Carboxytetramethylrhodamine (Tamra)-labelled reaction products were quantitated on a Typhoon scanner (GE Healthcare). Human APTX, 5 ml enzyme kinetic reactions contained human APTX (165-342) (2 nM), 59-AMP RNA-DNA (7.5-240 nM) or 59-AMP SSB (7.5-480 nM), in deadenylation reaction buffer and were incubated at 20 uC for 5 min. For S. cerevisiae Aptx Hnt3 , 5 ml enzyme kinetics reactions contained Aptx Hnt3 (8 nM, purchased from New England Biolabs), 59-AMP RNA-DNA (25 nM to 3.2 mM) or 59-AMP SSB (25 nM to 3.2 mM), in deadenylation reaction buffer, and were incubated at 20 uC for 5 min. Kinetic parameters were obtained from nonlinear regression fitting to a Michaelis-Menten model in Graphpad Prism.
Human APTX crystallization. Initial crystals of a human APTX-DNA-AMP-Zn complex (oligonucleotide 8, Extended Data Fig. 3d ) were grown by mixing complex solution 1 (10 mg ml 21 human APTX(165-342), 1 mM AMP, 1.5:1 DNA-protein ratio, in 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, and 0.1% b-mercaptoethanol) with an equal volume (300 nl) of the precipitant solution 1 (100 mM Tris, pH 8.5, 20% w/v polyethylene glycol 10000). Single crystals appeared after 2 weeks of incubation at 4 uC. Crystals of the human APTX-DNA-AMP product complex (oligonucleotide 9, Extended Data Fig. 3d ) were grown by mixing complex solution 2 (10 mg ml 21 human APTX(165-342), 1 mM AMP, 1:1 DNA:protein ratio, in 150 mM NaCl, 20 mM Tris-HCl, pH 7.5 and 0.1% b-mercaptoethanol) with an equal volume (300 nl) of precipitant solution 2 (150 mM magnesium acetate, 8% w/v polyethylene glycol 3350). Single crystals appeared overnight after incubation at 4 uC. Crystals of the human APTX/RNA-DNA-AMP product complex (oligonucleotides 6 and 7, Extended Data Fig. 3d ) were grown by mixing complex solution 3 (10 mg ml 21 Yeast strains. Saccharomyces cerevisiae strains used are isogenic derivatives of strain Dj(-2)j-7B-YUNI300 (MATa CAN1 his7-2 leu2-D::kanMX ura3-D trp1-289 ade2-1 lys2-DGG2899-2900 agp1::URA3-OR1 or OR2) 33 . Relevant strain genotypes are listed in Extended Data Table 1 . HNT3 deletion strains were generated by two experimental strategies. For the POL2 (Pol e-wild type) and pol2-M644G strains, diploids homozygous for the polymerase mutation (and rnh201D, where applicable) were made heterozygous for HNT3 (HNT3/hnt3D) by PCR-based targeted gene disruption. Deletion of one copy of the HNT3 gene was verified by PCR, haploids were obtained from tetrad dissections and were verified by PCR, appropriate drug-resistance and sequencing of the POL2 locus. Dissection plates were photographed after 3 days growth on rich medium (YPDA: 1% yeast extract, 2% bacto-peptone, 250 mg l 21 adenine, 2% dextrose, 2% agar for plates). For the pol2-M644L strains (6RNH201), deletion-replacement of HNT3 was performed via transformation with a PCR product containing the nourseothricin-resistance cassette (natMX4) amplified from pAG25 and flanked by 60 nucleotides of sequence homologous to the intergenic regions upstream and downstream of the HNT3 open reading frame. Transformants that arose from homologous recombination were verified by proper drug resistance and PCR analysis. Human APTX structure solution and refinement. Molecular replacement phases for the human APTX-DNA-AMP-Zn complex (complex 1) to 3.0 Å were obtained by using a systematic molecular replacement search varying ,190 model and data parameters in PHASER 34 , and testing multiple molecular constructs based on an S. pombe Aptx-DNA complex (3SZQ) (,29% identity with human APTX) 3 . The successful solution (PHASER TFZ 5 9.6, LLG 5 159, Refmac R free 5 48.9) contained four copies of human APTX in a P2 1 asymmetric unit (ASU). Map quality and molecular replacement phases were improved and extended to 2.5 Å using prime-and-switch density modification with NCS averaging in RESOLVE 35, 36 . The initial model was fit manually in O (v10.0) and partially refined in Refmac 37 . This model was then used for molecular replacement searches to phase the human APTX-RNA-DNA-AMP-Zn (at 1.95 Å , 2 molecules per ASU), human APTX-DNA-AMP-Zn (at 1.85 Å , 2 molecules per ASU), and human APTX(K197Q)-RNA-DNA-AMP-Zn product complexes (at 1.90 Å , 2 molecules per ASU). After autobuilding using PHENIX Autobuild 36 , models were fit manually in Coot 38 and refined in PHENIX 36 . The refined product RNA-DNA complex structure was used to phase the human APTX-RNA-DNA-adenosine-vanadate-Zn transition state complex (at 2.5 Å ). Final structures display excellent geometry (Extended Data Table 2 ) and refinement statistics. Yeast strain growth and HU-sensitivity analyses. Yeast strains were grown in YPDA at 30 uC. Growth curves were determined in duplicate; a representative plot RESEARCH LETTER is displayed. Strain doubling times (D t ) were calculated from measurements of the OD 600 nm of cultures in the logarithmic phase of growth in rich medium at 30 uC over a 17-h time course. D t measurements were made using data from four independent biological replicates (eight for the pol2-M644G hnt3D genotype) and the average D t 6 standard deviation is displayed. Statistical analysis (Fig. 2d ) was performed in GraphPad Prism. D'Agostino and Pearson omnibus normality test (alpha 5 0.05) is passed using doubling time determinations for the pol2-M644G hnt3D strain (n 5 8). The sample size is too small to run a normality test on the doubling time measurements for the hnt3D or pol2-M644G hnt3D rnh201D strains (n 5 4 for each). The coefficients of variations in the data are as follows: 11.4% for the hnt3D strain, 19.1% for the pol2-M644G hnt3D strain and 15.2% for the pol2-M644G hnt3D rnh201D strain. A spot dilution assay was performed by spotting tenfold serial dilutions of mid-log phase cultures onto YPDA agar 6 100 mM HU. Plates were incubated at 30 uC and photographed after 3 days of growth. A quantitative HU-survival assay was performed as described previously 12 . Exponentiallygrowing cells were arrested in G1 for 3 h with a-factor (5 mg ml 21 ). Approximately 500 cells from each strain were plated onto YPDA agar (untreated) or YPDA agar containing 100 mM HU, incubated for 3-6 days at 30 uC and counted. Percentage survival was calculated as the percentage of surviving cells compared to the untreated control. The experiment was performed in triplicate; data are displayed as the average 6 standard deviation.
Immunoblotting. Whole-cell extracts were prepared from exponentially growing cells as described 12 . The positive control is an extract prepared from wild-type cells treated with 200 mM HU for 3 h. Actin was probed as a loading control. Proteins were resolved on a 10% Bis-Tris gel (Life Technologies) and western blotting was performed using a 1:1,000 dilution of an affinity-purified rabbit polyclonal antibody against Rnr3 (Agrisera; AS09574). The anti-actin antibody (Millipore, MAB1501) was used at 1:1,000.
